---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-081404"
form_type: "8-K"
ticker: "HCWB"
cik: "0001828673"
company_name: "HCW Biologics Inc."
filed_at: "2025-06-04T23:59:59+00:00"
generated_at: "2026-05-20T00:11:10.422126+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# HCW Biologics earns $7M upfront license fee from WY Biotech for HCW11-006

## Summary
- $7.0M upfront fee earned; revenue to be recognized in Q2 2025.
- WY Biotech completed due diligence and confirmed commitment; agreement now fully binding.
- HCWB eligible for additional development milestones and double-digit royalties on future sales.
- HCWB has opt-in rights to recapture development/commercialization rights in U.S., Canada, Central and South America after Phase 1.
- WY Biotech bears all R&D, manufacturing, clinical, and commercialization costs; HCWB responsible only if it exercises opt-in.

## SEC filing metadata
- accession: 0000950170-25-081404
- form_type: 8-K
- ticker: HCWB
- cik: 0001828673
- company_name: HCW Biologics Inc.
- filed_at: 2025-06-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828673/000095017025081404/0000950170-25-081404-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828673/000095017025081404/hcwb-20250529.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-081404
- JSON: https://secwatch.observer/filing/0000950170-25-081404.json
- Plain text: https://secwatch.observer/filing/0000950170-25-081404.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.